Navigation Links
Healthscope to commercially launch Circadian's Cancers of Unknown Primary Diagnostic Test
Date:6/26/2012

etary rights, whether patent applications and issued patents will offer adequate protection to enable product development, the obtaining of necessary drug regulatory authority approvals and difficulties caused by the rapid advancements in technology.  Companies such as Circadian are dependent on the success of their research and development projects and on the ability to attract funding to support these activities.  Investment in research and development projects cannot be assessed on the same fundamentals as trading and manufacturing enterprises.  Thus investment in companies specialising in drug development must be regarded as highly speculative. Circadian strongly recommends that professional investment advice be sought prior to such investments.

Forward-looking statements

Certain statements in this ASX announcement may contain forward-looking statements regarding Company business and the therapeutic and commercial potential of its technologies and products in development.  Any statement describing Company goals, expectations, intentions or beliefs is a forward-looking statement and should be considered an at-risk statement.  Such statements are subject to certain risks and uncertainties, particularly those risks or uncertainties inherent in the process of developing technology and in the process of discovering, developing and commercialising drugs that can be proven to be safe and effective for use as human therapeutics, and in the endeavour of building a business around such products and services.  Circadian undertakes no obligation to publicly update any forward-looking statement, whether as a result of new information, future events, or otherwise.  Actual results could differ materially from those discussed in this ASX announcement.


'/>"/>
SOURCE Circadian Technologies Limited
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8

Related medicine technology :

1. PeriGen, Inc. Launches Consumer Safety Campaign to Raise Awareness of Dangerous Birth Complication
2. Varian X-Ray Products Business Launches On-Line Product Finder for Customers
3. Frost & Sullivan: Launch of New Classes of Oral Antidiabetic Drugs by 2014 will Uplift Prospects for the European Diabetes Therapeutics Market
4. Konica Minolta Sensing America Launches Spanish Website in Support of Growing Demand In Latin American Countries
5. Nouveau Life Pharmaceuticals (NOUV) to Launch Affiliate Sales Program
6. The Michael J. Fox Foundation Launches The $14 Million-Edmond J. Safra Core Programs for PD Research
7. Lifescript Launches New Online Asthma Health Center
8. AUA Foundation Launches Campaign to Address Stigma of Overactive Bladder
9. Office Star to Launch Safety Campaign at The Mobility Roadshow
10. Smith & Nephew launches two plating systems for foot and ankle surgeons at AOFAS annual meeting in San Diego
11. Lilly Diabetes Launches 8th Annual Diabetes Summer Camp Tour With Olympian Kris Freeman
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/28/2014)... Takeda Pharmaceutical Company Limited ("Takeda") today announced ... of data from a 10-year epidemiology study to ... (U.S.) Food and Drug Administration (FDA), ... Ministry of Health, Labour, and Welfare (MHLW) / ... for pioglitazone containing medicines, including ACTOS (pioglitazone HCl). ...
(Date:8/28/2014)... Resources Group finds that the market for colorectal cancer (CRC) ... in the United States , ... Italy , Spain , the ... . The biosimilar erosion of Roche/Genentech/Chugai,s Avastin and Bristol-Myers Squibb/Eli ... of Eli Lilly,s Cyramza, Taiho Pharmaceutical,s Lonsurf, Alchemia,s HA-irinotecan and ...
(Date:8/28/2014)... Aug. 28, 2014  A candidate Ebola vaccine could be given ... and Mali as early as September, ... aimed at preventing the disease that has killed more than 1,400 ... . Human trials of this candidate vaccine, being co-developed ... to be accelerated with funding from an international consortium in response ...
Breaking Medicine Technology:Takeda Announces Completion of the Post-Marketing Commitment to Submit Data to the FDA, the EMA and the PMDA for Pioglitazone Containing Medicines Including ACTOS 2Takeda Announces Completion of the Post-Marketing Commitment to Submit Data to the FDA, the EMA and the PMDA for Pioglitazone Containing Medicines Including ACTOS 3Takeda Announces Completion of the Post-Marketing Commitment to Submit Data to the FDA, the EMA and the PMDA for Pioglitazone Containing Medicines Including ACTOS 4Takeda Announces Completion of the Post-Marketing Commitment to Submit Data to the FDA, the EMA and the PMDA for Pioglitazone Containing Medicines Including ACTOS 5Takeda Announces Completion of the Post-Marketing Commitment to Submit Data to the FDA, the EMA and the PMDA for Pioglitazone Containing Medicines Including ACTOS 6The Colorectal Cancer Market Will Remain Steady at $7.7 Billion by 2023, With Biosimilar Erosion Of Key Agents Being Balanced Out By the Launch Of Premium-Priced Therapies 2Ebola vaccine trials fast-tracked by international consortium 2Ebola vaccine trials fast-tracked by international consortium 3Ebola vaccine trials fast-tracked by international consortium 4Ebola vaccine trials fast-tracked by international consortium 5Ebola vaccine trials fast-tracked by international consortium 6Ebola vaccine trials fast-tracked by international consortium 7
... of its commitment to supporting efforts to improve the ... has awarded $1,000 grants to ten health care organizations ... issues. (Logo: http://photos.prnewswire.com/prnh/20100412/DA84842LOGO ) ... the 2010 Beryl Institute Patient Experience grants are: ...
... PITTSBURGH, Oct. 19 Mylan Inc. (Nasdaq: MYL ... preferred stock issuance, the company has declared its quarterly dividend ... of 6.5% and a liquidation preference of $1,000.00 per share) ... of record as of Nov. 1, 2010.  Nov. 15, is ...
Cached Medicine Technology:Patient Experience Research Grants Awarded 2Patient Experience Research Grants Awarded 3
(Date:8/29/2014)... 29, 2014 According to The Madison-St. ... Pfizer Inc., Greenstone LLC and Pfizer R&D Cortex District ... defects as a result of using Zoloft during ... filed in St. Clair County Circuit Court (Case No. ... the defendant companies allegedly concealed the risks of serious ...
(Date:8/29/2014)... (PRWEB) August 29, 2014 Until now, ... (relational tables) or unstructured data (document stores). SQL products ... products have basically managed the wide assortment of unstructured ... to work with Big Data is with a NoSQL ... the various aspects of all Big Data issues. ...
(Date:8/28/2014)... August 29, 2014 Career Step, an ... released a new video designed to help students and ... coding and billing field. The video details what medical ... for these professionals, and the education requirements for entering ... option that’s often overlooked when people are considering a ...
(Date:8/28/2014)... (PRWEB) August 28, 2014 When David ... and long-time friend of Mark Brnovich, was asked to ... Republican nomination for the Attorney General seat in the ... quickly gathered the support of Cardinal Hall of Fame ... Cardinals Derek Kennard and Mark Walczak. Green, Kennard and ...
(Date:8/28/2014)... banker arrives at the emergency department with complaints ... alcohol every dayoften at business lunches, and at ... decided to quit drinking and had his last ... It,s a common scenario in emergency rooms across ... and develops withdrawal. , Withdrawal is a potentially ...
Breaking Medicine News(10 mins):Health News:The Law Office of Melinda J. Helbock A.P.C. Comments on Zoloft Birth Defect Lawsuit 2Health News:Scientel Announces Support for SQL Queries and Relational Tables Within Its Gensonix® NoSQL DB 2Health News:Scientel Announces Support for SQL Queries and Relational Tables Within Its Gensonix® NoSQL DB 3Health News:Scientel Announces Support for SQL Queries and Relational Tables Within Its Gensonix® NoSQL DB 4Health News:Career Step Releases New Video Designed to Help Students Explore the Medical Coding and Billing Field 2Health News:Pro Player Health Alliance Back in the Political Arena 2Health News:Pro Player Health Alliance Back in the Political Arena 3Health News:Real tremors, or drug-seeking patient? New app can tell 2Health News:Real tremors, or drug-seeking patient? New app can tell 3
... Inhibiting a protein involved in bone metabolism can delay the ... with a particular form of prostate cancer, a researcher will ... Professor Stphane Oudard, Head of ... says that his team,s research on the effects of the ...
... for prostate cancer will be unveiled at the 2011 ... Led by Dr David rsted at the Copenhagen University ... with benign prostate enlargement have an increased risk of ... shows that monitoring prostate-specific antigen levels can be used ...
... News) -- People,s bodies build up vitamin D through exposure ... live in areas of the United States with low sunlight ... who live in the same places. The researchers say ... change. "This study shows that across-the-board vitamin D recommendations just ...
... -- Although some studies have suggested that men can ... their voices, a new study appears to dispel that notion ... women are ovulating by examining changes in their voices over ... Unlike previous studies, the researchers behind the new study ...
... Chronic Disease Alliance (ECDA)1 welcomes the UN High Level Meeting ... killers. "It is a memorable day in the history ... table gives a strong sense of the burden it represents ... challenge for all nations in the world2", declared Professor Michel ...
... 23 (HealthDay News) -- New research suggests that depression ... have survived breast cancer from getting screenings that could ... "Depression can make people more inattentive to potential ... recommendations to reduce their risk," said study researcher Amelie ...
Cached Medicine News:Health News:New bone-targeting drug delays onset of metastases in hormone-resistant prostate cancer patients 2Health News:New bone-targeting drug delays onset of metastases in hormone-resistant prostate cancer patients 3Health News:New bone-targeting drug delays onset of metastases in hormone-resistant prostate cancer patients 4Health News:2 new cost-effective ways to predict prostate cancer 2Health News:2 new cost-effective ways to predict prostate cancer 3Health News:2 new cost-effective ways to predict prostate cancer 4Health News:Many Black Men in Cold Climates Lack Vitamin D 2Health News:Non-communicable diseases at the center of UN discussions 2Health News:Depression After Cancer Keeps Some From Follow-Up Care 2
15mm Open Blades, 28mm Maximum Spread; Available in small(S) and large (L), in stainless steel....
9mm Gently Curved Jaws, without lock; in Titanium....
8mm angled shaft with tip at 90 degree angle wtih rounded tear drop point; Tip available in left, right and center; (Right-SQT-225 and Left -SQT-227) In Titanium....
2.0mm Rounded Tip, 12mm From Tip to Bend Gently Curved, 15mm Shaft; In Titanium...
Medicine Products: